Nayan M - Search Results

1

Active surveillance for intermediate-risk prostate cancer.

Nayan M, Carvalho FLF, Feldman AS. Nayan M, et al. World J Urol. 2022 Jan;40(1):79-86. doi: 10.1007/s00345-021-03893-1. Epub 2022 Jan 19. World J Urol. 2022. PMID: 35044491 Review.

2

A machine learning approach to predict progression on active surveillance for prostate cancer.

Nayan M, Salari K, Bozzo A, Ganglberger W, Lu G, Carvalho F, Gusev A, Schneider A, Westover BM, Feldman AS. Nayan M, et al. Urol Oncol. 2022 Apr;40(4):161.e1-161.e7. doi: 10.1016/j.urolonc.2021.08.007. Epub 2021 Aug 29. Urol Oncol. 2022. PMID: 34465541 Free PMC article.

3

Predicting survival after radical prostatectomy: Variation of machine learning performance by race.

Nayan M, Salari K, Bozzo A, Ganglberger W, Carvalho F, Feldman AS, Trinh QD. Nayan M, et al. Prostate. 2021 Dec;81(16):1355-1364. doi: 10.1002/pros.24233. Epub 2021 Sep 16. Prostate. 2021. PMID: 34529282

4

Preoperative anemia is associated with increased radical cystectomy complications.

Carvalho FLF, Wang Y, Dall CP, Nayan M, Chou WH, McGregor B, Stopfkuchen-Evans MF, Stamatakis L, Preston MA, Kibel AS, Chang SL, Mossanen M. Carvalho FLF, et al. Among authors: nayan m. Urol Oncol. 2022 Aug;40(8):382.e7-382.e13. doi: 10.1016/j.urolonc.2022.04.014. Epub 2022 Jun 8. Urol Oncol. 2022. PMID: 35690547

5

Editorial Comment.

Nayan M, Fleshner N, Bozzo A. Nayan M, et al. J Urol. 2019 Sep;202(3):504-505. doi: 10.1097/01.JU.0000558548.34484.39. Epub 2019 Aug 8. J Urol. 2019. PMID: 31166882 No abstract available.

6

Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.

Nayan M, Jewett MA, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, Hansen AR, Chung P, Warde P, Sweet J, O'Malley M, Atenafu EG, Hamilton RJ. Nayan M, et al. Eur Urol. 2017 Jan;71(1):120-127. doi: 10.1016/j.eururo.2016.07.013. Epub 2016 Aug 12. Eur Urol. 2017. PMID: 27527805

7

Opioid Use After Nephrectomy for Kidney Cancer in Ontario: A Population-Based Study.

Cheung DC, Martin LJ, Jivraj NK, Clarke H, Gomes T, Wijeysundera DN, Diong C, Nayan M, Saarela O, Alibhai SMH, Komisarenko M, Fleshner NE, Kulkarni GS, Finelli A. Cheung DC, et al. Among authors: nayan m. Urology. 2022 Jun;164:118-123. doi: 10.1016/j.urology.2022.02.002. Epub 2022 Feb 16. Urology. 2022. PMID: 35182588

8

Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer.

Nayan M, Hamilton RJ. Nayan M, et al. Adv Urol. 2018 Feb 19;2018:7182014. doi: 10.1155/2018/7182014. eCollection 2018. Adv Urol. 2018. PMID: 29670653 Free PMC article. Review.

9

Statin use and time to progression in men on active surveillance for prostate cancer.

Jayalath VH, Nayan M, Finelli A, Komisarenki M, Timilshina N, Kulkarni GS, Fleshner NE, Bhindi B, Evans A, Zlotta AR, Hamilton RJ. Jayalath VH, et al. Among authors: nayan m. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):509-515. doi: 10.1038/s41391-018-0053-x. Epub 2018 Jun 6. Prostate Cancer Prostatic Dis. 2018. PMID: 29875433

10

Circumcision and Risk of HIV among Males from Ontario, Canada.

Nayan M, Hamilton RJ, Juurlink DN, Austin PC, Jarvi KA. Nayan M, et al. J Urol. 2022 Feb;207(2):424-430. doi: 10.1097/JU.0000000000002234. Epub 2021 Sep 23. J Urol. 2022. PMID: 34551593

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page